

---

## Mayo Clinic presents first clinical case with EndoDrill® GI in the lower GI tract at ESGE Days 2026

BiBBInstruments AB (“BiBB” or the “Company”) announces that physicians at world-renowned Mayo Clinic in Jacksonville, Florida, presented clinical experience with EndoDrill® GI at ESGE Days 2026. The presented case demonstrated successful endoscopic ultrasound-guided core biopsy using EndoDrill® GI of a lesion adjacent to the rectum. The biopsy resulted in ample tissue acquisition in a single pass and without reported adverse events.

*“We are encouraged to see Mayo Clinic present additional clinical experience with EndoDrill® GI, this time in the lower GI tract. The findings confirm the instrument’s ability to obtain high-quality core tissue in situations where conventional biopsy approaches may be particularly challenging,”* said Charles Walther, CMO and Founder of BiBBInstruments.

The presentation by authors from the Division of Gastroenterology and Hepatology at Mayo Clinic, Jacksonville, Florida, entitled *“EndoDrill-Assisted EUS Biopsy: Unmasking an extrinsic rectal mass”*, describes a case involving a 72-year-old patient with a pelvic mass extending toward the rectum. Histopathology and immunohistochemistry from the EndoDrill® GI biopsy confirmed high-grade urothelial carcinoma. The authors noted that this is, to their knowledge, the first reported use of EndoDrill® GI for tissue acquisition in the lower GI tract.

According to the authors, ample core tissue was obtained in a single pass without adverse events. The authors further conclude that EndoDrill® GI demonstrates *“significant potential to enhance diagnostic yield of EUS-CNB.”*

ESGE Days is organized by the European Society of Gastrointestinal Endoscopy (ESGE) and gathers leading physicians, researchers, and medtech companies focused on advanced endoscopy from around the world.

### **About Mayo Clinic and the Use of EndoDrill® GI**

Mayo Clinic in Jacksonville, Florida, is part of Mayo Clinic, one of the world’s leading hospital systems and consistently ranked among the top hospitals in the United States. The clinic is internationally recognized for, among other things, advanced endoscopy, gastroenterology, and cancer diagnostics.

In 2025, Mayo Clinic researchers presented a poster demonstrating the potential of EndoDrill® GI to obtain high-quality tissue cores from pancreas lesions with lower blood contamination compared with conventional needles.

### **About EndoDrill® GI**

EndoDrill® GI is the world’s first market-cleared powered biopsy instrument for endoscopic ultrasound (EUS), with both FDA 510(k) clearance and CE marking. Unlike conventional manual biopsy needles, EndoDrill® uses a powered rotating needle tip designed to obtain intact core tissue samples for histopathology and molecular analysis. The system is currently being commercialized in the United States together with distribution partner TaeWoong Medical USA.

---

**For more information, please contact:**

Fredrik Lindblad, CEO

Email: [fredrik.lindblad@bibbinstruments.com](mailto:fredrik.lindblad@bibbinstruments.com)

Phone: +46 70 899 94 86

[www.bibbinstruments.com](http://www.bibbinstruments.com)

*This is a translation of the Swedish press release. In the event of any discrepancy, the Swedish language version shall prevail.*

*The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor upon publication of this press release.*

**About BiBBInstruments AB**

BiBBInstruments AB is a cancer diagnostics company developing and manufacturing EndoDrill<sup>®</sup>, the world's first series of market-cleared powered endoscopic biopsy instruments. EndoDrill<sup>®</sup> is designed to obtain core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancers in organs such as the stomach, pancreas, liver, lungs, and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments within modern endoscopy. BiBB received FDA 510(k) clearance for its first instrument, EndoDrill<sup>®</sup> GI, in 2023 and CE marking under the European Medical Device Regulation (MDR) in 2024 for all three product variants – EndoDrill<sup>®</sup> GI, EndoDrill<sup>®</sup> EBUS, and EndoDrill<sup>®</sup> URO. As such, EndoDrill<sup>®</sup> is the first powered biopsy system cleared in both the United States and Europe. The U.S. launch of EndoDrill<sup>®</sup> GI commenced during the second half of 2025 in collaboration with TaeWoong Medical USA. The EndoDrill<sup>®</sup> system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant pathologist at Skåne University Hospital. The Company is headquartered at Medicon Village in Lund, Sweden, and its shares are listed on Spotlight Stock Market (ticker: BIBB).